FDA Inspection 1073695 — Antares Pharma, Inc.

Antares Pharma, Inc. — FEI 2182861

The FDA completed an inspection of Antares Pharma, Inc. on Dec 4, 2018 in Minnetonka, MN. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 1 citation was issued during this inspection. Product area: Devices.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Dec 4, 2018
Fiscal Year
2019
Product Type
Devices
Project Area
Compliance: Devices
Location
Minnetonka, MN (United States)

Citations

IDCFRDescription
369621 CFR 820.100(b)Documentation

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.